相关实验视频

Updated: Jan 7, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

甲福明通过免疫调节和FABP4/FOXO1轴减轻糖尿病驱动的衰老

Nawal M Alrasheed¹, Lama A Almuthanbi¹, Rana R Alotaibi¹

¹Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

Pharmaceuticals (Basel, Switzerland)

|December 31, 2025

概括

甲福明通过向脂肪酸结合蛋白4 (FABP4) /分叉盒蛋白O1 (FOXO1) 途径和关键酶来减少糖尿病大鼠的脏衰老,为糖尿病脏病提供潜在的免疫代谢疗法.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
内分泌学在内分泌学.
免疫学免疫学免疫学

背景情况:

糖尿病病 (DN) 通过炎症和代谢问题加速衰老.
甲福明在减轻糖尿病驱动的衰老中的确切作用尚未完全理解.
本研究探讨了甲福明对FABP4/FOXO1轴和DN中的免疫代谢酶的影响.

研究的目的:

调查甲福明是否可以降低糖尿病诱导的衰老.
确定甲福明是否调节FABP4/FOXO1轴和DN中的关键免疫代谢酶.
评估甲福明对糖尿病脏炎症和巨细胞两极分化的影响.

主要方法:

患有2型糖尿病的Wistar大鼠接受了10周的甲福明或盐水治疗.
评估功能,脂质样本,炎症性细胞因子和衰老标志物.
评估了FABP4/FOXO1表达,巨细胞透和组织学.

主要成果:

甲福明改善了功能,使脂质正常化,并减少了炎症性细胞因子 (IL-6,TNF-α),同时增加了IL-10.
它逆转了酸脱酶 (SDH) 和ATP-酸酶 (ACLY) 活性的改变.
甲胺降低了FABP4,FOXO1和P16INK4a的调节,减少了巨细胞的透,促进了M2极化,改善了脏结构.

结论:

甲福明通过向FABP4/FOXO1轴和免疫代谢酶SDH和ACLY来缓解糖尿病衰老.
这些发现表明甲胺是糖尿病脏病的潜在免疫代谢和免疫化导向疗法.
这项研究提供了对美特福林在DN中的多面保护机制的新见解.

关键词:

糖尿病性脏病糖尿病脏病脂肪酸结合蛋白 4 脂肪酸结合蛋白叉盒蛋白质 1 1 叉盒蛋白质免疫代谢的免疫代谢免疫性免疫性免疫性甲胺是一种甲胺.

更多相关视频

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...